An observational study in Multiple Sclerosis, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Completed at 1 site in Argentina. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-10-22.
Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Multiple Sclerosis with a site in Argentina — 4 open to participants now, 13 under way, 10 of them phase 3. Multiple Sclerosis · Argentina.
Among the 53 studies in Multiple Sclerosis with a site in Argentina, this one is the 16th largest by enrollment of the 18 observational ones that give a count, is one of 3 that started in 2010, is one of 18 observational ones, and was the 27th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 53 studies in Multiple Sclerosis with a site in Argentina are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, United States, Australia and 33 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Argentina, Brazil, Mexico and 4 more countries
Ages 10–17
Novartis Pharmaceuticals · Sites in Argentina, United States, Australia and 16 more countries
Ages 40–70
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul · Sites in Argentina, United States, Australia and 14 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 835 across the 35 interventional studies, 453 across the 18 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 53 have an industry lead sponsor. The 10 most frequent:
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Multiple Sclerosis with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07161258Hoffmann-La RocheA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | 2027-06-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Multiple Sclerosis with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recently, it has been shown that salt (ClNa, sodium chloride) can modulate the differentiation of human and mouse TH17 cells. Indeed, mice feed with high sodium diet were described to develop more aggressive course of EAE (Experimental Autoimmune Encephalitis).
However, the role of sodium intake in MS has not been investigated. In this study we investigate the effect of sodium intake in Multiple Sclerosis (MS) clinical and radiological activity.
A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were recruited from the MS clinic at FLENI by attending neurologists. A second group of 52 relapsing-remitting MS patients was recluted later.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MS patients
Exacerbation rate
Number of disease relapses during follow up time according to salt consumption
Time frame: 2 years
Radiological activity
Number of new lesions in MRI
Time frame: One year
The record gives a start of Nov 2010, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia